Skip to main content

NICE TAs

21/04/2020
TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
21/04/2020
TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
21/04/2020
TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
21/04/2020
TA597: Dapagliflozin with insulin for treating type 1 diabetes
21/04/2020
TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
21/04/2020
TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
21/04/2020
TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
21/04/2020
TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
21/04/2020
TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
21/04/2020
TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line
21/04/2020
TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
16/04/2020
TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
16/04/2020
TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
16/04/2020
TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
16/04/2020
TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
15/04/2020
TA627: Lenalidomide with rituximab for previously treated follicular lymphoma
05/03/2020
TA367: Vortioxetine for treating major depressive episodes

Published date: We reviewed the evidence in November 2018. We found nothing new that affects the recommendations in this guidance.

05/03/2020
TA272: Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

Published date: We reviewed the evidence in January 2016. We found nothing new that affects the recommendations in this guidance.

05/03/2020
TA179: Sunitinib for the treatment of gastrointestinal stromal tumours

Published date: We reviewed the evidence in July 2017. We found nothing new that affects the recommendations in this guidance.

05/03/2020
TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

Published date: We reviewed the evidence in March 2018. We found nothing new that affects the recommendations in this guidance.

Follow AWTTC: